FM (chemotherapy)

FM in the context of chemotherapy means a chemotherapy regimen used as first-line therapy in indolent lymphomas. In combination with rituximab it is called R-FM or RFM or FM-R or FMR.

The [R]-FM regimen consists of:

  1. (R)ituximab - an anti-CD20 monoclonal antibody that is able to kill both normal B cells and malignant ones;
  2. (F)ludarabine - an antimetabolite;
  3. (M)itoxantrone - a synthetic antracycline analogue (an antraquinone) that is able to intercalate DNA and prevent mitosis.[1]

This regimen is also sometimes used in some autoimmune disorders that are inherently sensitive to rituximab, fludarabine and mitoxantrone in monotherapies (e.g. multiple sclerosis).

Dosing regimen

Drug Dose Mode Days
(R)ituximab 375 mg/m2 IV infusion Day 1
(F)ludarabine 25 mg/m2 IV infusion Days 1-3
(M)itoxantrone 10 mg/m2 IV infusion Day 1

References

  1. ↑ Fludarabine Plus Mitoxantrone With and Without Rituximab Versus CHOP With and Without Rituximab As Front-Line Treatment for Patients With Follicular Lymphoma
This article is issued from Wikipedia - version of the 6/29/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.